SOURCE: Market Pulse

June 14, 2007 08:30 ET

Market Pulse Breaking News Alert for Thursday, June 14, 2007: HBSC - Human BioSystems Announces Acceptance of a Professional Paper in the Journal of Investigative Surgery and Its Solution Outperforms the Gold Standards in the Industry!

NOTE TO EDITORS: The Following Is an Investment Opinion Being Issued by Market Pulse.

ATLANTA, GA--(Marketwire - June 14, 2007) - Market Pulse News Alert for this AM, Stocks to Watch are: Human BioSystems (OTCBB: HBSC), Intel Corp. (NASDAQ: INTC), Generex Biotechnology Corp. (NASDAQ: GNBT) and Hoku Scientific Inc. (NASDAQ: HOKU).

Investors need to be watching Human BioSystems (OTCBB: HBSC) this AM! Human BioSystems is a leader in the development of preservation platform technologies that provide safe, high quality, and longer shelf lives for organs, tissue, cells and other biomaterials that are used in saving lives. Human BioSystems' proprietary preservation systems for initial products consist of non-toxic liquid solutions, proprietary protocols and solutions. These systems do not employ toxic preservatives or special cryogenic techniques or complex equipment. HBSC specializes in the development of proprietary above zero (HBS-AZ) and below zero (HBS-BZ) organ and tissue preservation systems and methods for preserving blood platelets. HBSC has five issued patents (with others pending) for technologies that preserve platelets and organs such as the kidney, heart, liver, and lung. The company's unique patent-pending technology could double the storage period for platelets, may dramatically reduce bacterial growth and may maintain better platelet functionality. The company has been successful in preserving blood platelets for ten days under refrigeration while maintaining cell structure and morphology, which has never been done before to HBSC's knowledge. HBSC is expected to be a major supplier to the industry with their improved platelet storage technology. HBSC's technology and equipment may allow blood centers and hospitals to recover more than $500 million in lost revenue annually in North America, Western Europe and Japan. The company's target customers include blood banks, hospitals, clinics, and similar organizations. Human BioSystems is seeking strategic partners for the preservation technology and licensee of the HBS-AZ preservation solution for organs preservation. Terms will include license fees and royalty for marketing and distribution rights. The company estimates a multi-billion dollar market demand for its platelet and organ preservation system coupled with the post-transplant technology. HBSC is looking for additional products that are close to commercialization to add to its pipeline. Human BioSystems' wholly owned subsidiary HBS BioEnergy (HBSE) is engaged in the business of bio-fuels production, with a team focused on locating, constructing and operating bio-fuels facilities using cutting-edge technologies. The company commenced operations in September of 2006, pursuant to a definitive agreement signed between HBS BioEnergy and EXL III Group Corporation, whereby Claude Luster, III became HBSE's president. HBSE believes the ethanol industry has substantial potential for growth. HBS BioEnergy recently formed a joint venture with Visalia-based Dairy Development Group and Agrimass Enviro-Energy to build an Energy Park in the San Joaquin Valley of California. The Energy Park will utilize waste from surrounding dairies to provide the power needed to fuel a proposed ethanol plant to be located on site. Human BioSystems is poised to become a significant player in the biomedical and bioenergy industries! HBSC has had several excellent news announcements out lately and one again before today's opening bell announcing the acceptance for publication of a professional paper evaluating its unique preservation solution in the Journal of Investigative Surgery! This could be great news for investors!

Human BioSystems (OTCBB: HBSC), a Silicon Valley-based bio-tech company specializing in the development of unique organ, tissue and cellular preservation platforms and holder of five U.S. patents covering such technologies, has just been notified of the acceptance of a professional paper describing its unique cold-storage preservation solution by the peer-reviewed Journal of Investigative Surgery.

Luis H. Toledo, M.D., Ph.D., a leading transplantation surgeon and Director of the HBS Research Laboratory, stated, "In this study, the HBS solution out-performed preservation solutions currently considered to be the 'gold standards' in the industry." Dr. Fernando Lopez-Neblina, co-author of the paper, praised the publication saying, "This is evidence that corroborates the significant benefits of the physiologic support we have incorporated in this next generation of preservation solutions."

The HBS paper highlights the significant attributes afforded by the HBS cold preservation solution, comparing it with the other leading solutions in the field. HBS-treated rat organs out-performed the others in survival, function, microscopic appearance and assessment using the Reperfusion Damage Index (RDI).

In addition to the current cold (0°C to -4°C) preservation solution described in this publication, HBS has developed and is testing preservation solutions intended for the freezing of biological tissues. Preservation solutions able to extend the life of organs while simultaneously improving function will enable transplant centers to ensure better matches between the transplanted organs and the recipients. This will translate into better organ function and less rejection.

Dr. David Winter, President of HBS, said, "The acceptance of our paper by such a respected publication as the Journal of Investigative Surgery is suggestive of our progress in advancing biologic preservation science. We are currently in discussion with other transplant centers to corroborate and extend the current results. Our ultimate goal in this area of our preservation business is to establish market share in the transplantation solution arena."

Stocks in the news and acting well as of late include: Intel Corp. (NASDAQ: INTC), Generex Biotechnology Corp. (NASDAQ: GNBT) and Hoku Scientific Inc. (NASDAQ: HOKU).

Information contained herein is the opinion of ("MP") and is intended to be used strictly for informational purposes. You should be aware that MP attempts to assure itself of the accuracy of the information contained in the analyses it publishes. In this regard, MP does, at times, rely on the accuracy of information supplied to it by the companies which are the subject of MP's analyses and/or parties related to those companies. MP also relies on the accuracy and integrity of information that is contained in company press releases and reports filed with the SEC. The companies mentioned in this publication have not approved the content or timing of the information being published unless otherwise noted.

MP, because it relies on information supplied by various third parties disclaims any responsibility for the accuracy of such information. Any investor considering making an investment in any security which has been the subject of a MP analysis or opinion should, before making any such investment, consult with his/her market professional and/or do his/her own independent research regarding the company which is the subject of an MP opinion, recommendation or analysis. Information regarding companies which MP has opined upon is normally available from many sources including the subject company's filings with the SEC and various press releases issued by the company.

You should be aware that MP is often compensated for issuing analyses, recommendations or opinions concerning particular companies. Its opinion is therefore not unbiased and you should consider this factor when evaluating MP's statements regarding a company. MP has been compensated in free trading shares of common stock, available for public trading as follows: Human BioSystems compensation from the company: six hundred seventy five thousand free trading shares of stock in Human BioSystems already received from the company. In addition, MP in the open market previously purchased one hundred thousand shares of stock in Human BioSystems for a total purchase price of eight thousand forty dollars. To date, MP has sold four hundred seventy five thousand shares of stock in Human BioSystems for proceeds totaling fifty one thousand nine hundred dollars. MP's officers and directors reserve the right to buy additional shares of the companies discussed in this opinion and may profit in the event those shares rise in value. When MP receives free trading shares as compensation for a profiled company, MP may sell part or all of any such shares during the period in which MP is performing such services. and Market Pulse Breaking News Alert are owned by Market Pulse LLC.

Contact Information